NovoCure Limited · NASDAQ:NVCR

NovoCure — Fact Sheet (January 2023)

4 slides from NovoCure's fact sheet, January 2023

  1. Slide 1: building a global oncology company

    building a global oncology company Founded in 2000, Novocure develops and commercializes an innovative therapy for solid tumors: Tumor Treating Fields (TTFields). After more than 20 years, Novocure continues to grow, fueled by a collective drive for innovation.

  2. Slide 2: our growth, at a glance

    our growth, at a glance + + 26,000 1,300 PATIENTS TREATED TO DATE EMPLOYEES WORLDWIDE 4 INDICATIONS IN 3 FDA APPROVED LATE-STAGE PIPELINE INDICATIONS Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercial

  3. Slide 3: our pipeline

    TTFIELDS THERAPY IS A PLATFORM THERAPY, WITH SIGNIFICANT POTENTIAL FOR VERSATILITY ACROSS SOLID TUMOR TYPES AND LINES OF THERAPY. “We are diligently working to reach additional patients in our current markets, expand into new markets, enhance our products and treat patients in new indications.” – Wi

  4. Slide 4: our global footprint

    our global footprint Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. Our active markets are below. SWEDEN CANADA GERMANY SWITZERLAND AUSTRIA FRANCE U

Novocure — Fact Sheet (January 2023) on 6ix